The results showed that no correlation was observed between CLDN3 downregulation and patient's gender, age, HbsAg, serum AFP, tumor size, cirrhosis, tumor cell differentiation, recurrence and tumor stage. This evidence concerns the gene CLDN3 and Cirrhosis.